Copyright
©The Author(s) 2023.
World J Gastroenterol. Sep 21, 2023; 29(35): 5154-5165
Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5154
Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5154
Table 3 Correlation between heparanase and LC3B and acute gastrointestinal injury grade in the two groups
| Control group | Intervention group | ||||||||
| LC3B (μg/mL) | AGI grade | LC3B (μg/mL) | AGI grade | ||||||
| HPA (ng/mL) | Day 1 | r = -0.8394 | P < 0.001 | r = 0.8441 | P < 0.001 | r = -0.8456 | P < 0.001 | r = 0.7106 | P < 0.001 |
| Day 3 | r = -0.9545 | P < 0.001 | r = 0.7670 | P < 0.001 | r = -0.8882 | P < 0.001 | r = 0.8135 | P < 0.001 | |
| Day 7 | r = -0.8258 | P < 0.001 | r =0.7657 | P < 0.001 | r = -0.8724 | P < 0.001 | r = 0.7839 | P < 0.001 | |
- Citation: Chen TT, Lv JJ, Chen L, Li M, Liu LP. Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis. World J Gastroenterol 2023; 29(35): 5154-5165
- URL: https://www.wjgnet.com/1007-9327/full/v29/i35/5154.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i35.5154